Evotec Receives a Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec. The milestone reached was the selection of a candidate compound for pre-development studies in an inflammation and immunology programme.
Dr Werner Lanthaler, Chief Executive Officer of Evotec commented: "This is the tenth milestone achieved since the inception of the collaboration between Boehringer Ingelheim and Evotec in 2004, thus underlining the great success of one of the largest and most significant global research alliances between pharma and biotech."
Organizations
Other news from the department research and development
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.